FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small ...
Nearly 90% of patients in the MINT trial tapered prednisone to 5 mg/day or less, with no significant safety concerns seen to ...
IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.
Once weekly tirzepatide significantly reduces body mass index in adolescents with obesity compared with placebo.
Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.
Rural patients with HFrEF had lower mortality when treated at urban hospitals but higher early mortality than urban patients ...
Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, ...
San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy ...
In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ...
Building a third-line treatment framework starts with molecular profile and available targeted options, but ultimately rests ...
In 2024, physicians face significant financial challenges due to declining Medicare reimbursement rates and high student loan interest rates, which will impact health care delivery and access. In 2024 ...
The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR ...